Compare NDRA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDRA | IMRN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 9.4M |
| IPO Year | 2016 | 2016 |
| Metric | NDRA | IMRN |
|---|---|---|
| Price | $4.97 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.1K | ★ 61.5K |
| Earning Date | 11-16-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.39 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $0.68 |
| 52 Week High | $6.95 | $2.35 |
| Indicator | NDRA | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 33.93 |
| Support Level | $4.87 | $0.77 |
| Resistance Level | $4.90 | $1.00 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 9.73 | 8.45 |
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.